Clinical trial

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2026-02-20

PhasePHASE2

Study timeline

Study start (actual)2026-02-20Date precision: day

Registry last updated2026-09-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-proliferative Diabetic Retinopathy (NPDR)unresolved

Open-angle Glaucoma (OAG)unresolved

Normal Tension Glaucoma (NTG)unresolved

Interventions

QLS-111 Ophthalmic Solution (0.015%)DRUG

QLS-111 Ophthalmic Solution (0.075%)DRUG

Sponsors & collaborators

Qlaris Bio, Inc.lead sponsor

Mapped research locations

Palo AltoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07354477 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.